Tivozanib

Phase 3

Aveo Pharmaceuticals, Inc. (AVEO)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Nov '26

AVEOPhase 2

Tivozanib Phase 2 Est. Readout

Tivozanib• Renal Cell Carcinoma48

Nov 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Renal Cell Carcinoma

View Full Landscape

Drug Information

Target Indication

Renal Cell Carcinoma

Clinical Trial

NCT01297244

Last updated: 12/29/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

AVEO

Aveo Pharmaceuticals, Inc.

Healthcare•North America•NASDAQ

Related Pipeline

FiclatuzumabPhase 3

Metastatic Head-and-neck Squamous-cell Carcinoma

Tivozanib hydrochloridePhase 3

Carcinoma, Renal Cell

Samalizumab (BAML-16-001-S1)Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

tivozanib (AV-951)Phase 3

Advanced Renal Cell Carcinoma

mFOLFOX6Phase 2

Colorectal Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts